IUPAC/Chemical Name
3-(Aminooxymethyl)-6-bromphenol
InChi Key
QNWOSJAGFSUDFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H8BrNO2/c8-6-2-1-5(4-11-9)3-7(6)10/h1-3,10H,4,9H2
SMILES Code
OC1=C(Br)C=CC(CON)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
218.05
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lingappa JR, Zigmond RE. Limited recovery of pineal function after regeneration of preganglionic sympathetic axons: evidence for loss of ganglionic synaptic specificity. J Neurosci. 2013 Mar 13;33(11):4867-74. doi: 10.1523/JNEUROSCI.3829-12.2013. PubMed PMID: 23486957; PubMed Central PMCID: PMC3640627.
2: Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004 Mar;1012:306-25. PubMed PMID: 15105275.
3: Arrue A, Ruiz-Ortega JA, Ugedo L, Giralt MT. Short-term effects of 3,4-methylenedioximethamphetamine on noradrenergic activity in locus coeruleus and hippocampus of the rat. Neurosci Lett. 2003 Feb 13;337(3):123-6. PubMed PMID: 12536039.
4: Arbogast LA, Voogt JL. Hypoprolactinemia decreases tyrosine hydroxylase activity in the tuberoinfundibular dopaminergic neurons acutely by protein dephosphorylation and chronically by changes in gene expression. Endocrine. 1995 Nov;3(11):801-6. doi: 10.1007/BF02935684. PubMed PMID: 21153124.
5: Arbogast LA, Voogt JL. Progesterone suppresses tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nucleus on proestrus. Endocrinology. 1994 Jul;135(1):343-50. PubMed PMID: 7912184.
6: Jumblatt JE. Prejunctional alpha 2-adrenoceptors and adenylyl cyclase regulation in the rabbit iris-ciliary body. J Ocul Pharmacol. 1994 Winter;10(4):617-21. PubMed PMID: 7714405.
7: Arbogast LA, Soares MJ, Robertson MC, Voogt JL. A factor(s) from a trophoblast cell line increases tyrosine hydroxylase activity in fetal hypothalamic cell cultures. Endocrinology. 1993 Jul;133(1):111-20. PubMed PMID: 8100518.
8: Scherkl R, Hashem A, Frey HH. Histamine in brain--its role in regulation of seizure susceptibility. Epilepsy Res. 1991 Nov-Dec;10(2-3):111-8. PubMed PMID: 1817952.
9: Arbogast LA, Voogt JL. Mechanisms of tyrosine hydroxylase regulation during pregnancy: evidence for protein dephosphorylation during the prolactin surges. Endocrinology. 1991 Nov;129(5):2575-82. PubMed PMID: 1682138.
10: Dahmer MK, Hart PM, Perlman RL. Insulin-like growth factor-I enhances tyrosine hydroxylase activation in bovine chromaffin cells. J Neurochem. 1991 Oct;57(4):1347-53. PubMed PMID: 1680164.
11: Sagrillo CA, Voogt JL. Endogenous opioids mediate the nocturnal prolactin surge in the pregnant rat. Endocrinology. 1991 Aug;129(2):925-30. PubMed PMID: 1906806.
12: Arbogast LA, Voogt JL. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. Endocrinology. 1991 Feb;128(2):997-1005. PubMed PMID: 1703487.
13: Scherkl R, Hashem A, Frey HH. Importance of histamine for seizure susceptibility. Agents Actions Suppl. 1991;33:85-9. PubMed PMID: 1675837.
14: Spina MB, Cohen G. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther. 1988 Nov;247(2):502-7. Erratum in: J Pharmacol Exp Ther 1989 Jan;248(1):478. PubMed PMID: 3183949.
15: Kittner B, Bräutigam M, Herken H. PC12 cells: a model system for studying drug effects on dopamine synthesis and release. Arch Int Pharmacodyn Ther. 1987 Apr;286(2):181-94. PubMed PMID: 2439033.
16: Misu Y, Goshima Y, Kubo T. Biphasic actions of L-DOPA on the release of endogenous dopamine via presynaptic receptors in rat striatal slices. Neurosci Lett. 1986 Dec 12;72(2):194-8. PubMed PMID: 3808473.
17: Goshima Y, Kubo T, Misu Y. Biphasic actions of L-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices. Br J Pharmacol. 1986 Sep;89(1):229-34. PubMed PMID: 3801773; PubMed Central PMCID: PMC1917033.
18: Abou-Donia MM, Wilson SP, Zimmerman TP, Nichol CA, Viveros OH. Regulation of guanosine triphosphate cyclohydrolase and tetrahydrobiopterin levels and the role of the cofactor in tyrosine hydroxylation in primary cultures of adrenomedullary chromaffin cells. J Neurochem. 1986 Apr;46(4):1190-9. PubMed PMID: 2869107.
19: Grzanna R. Histidine decarboxylase: isolation and molecular characteristics. Neurochem Res. 1984 Jul;9(7):993-1009. PubMed PMID: 6504233.
20: Oide M. Effect of alpha-methyldopa on alpha-noradrenergic receptor binding sites in the mouse brain. Pharmacology. 1984;28(3):130-8. PubMed PMID: 6326166.
